No Data
No Data
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics Analyst Ratings
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $4
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5